COVID-19 infection with delayed presentation of infective endocarditis of the prosthetic pulmonary valve

Abstract

Pulmonary valve endocarditis after transcatheter pulmonary valve implantation has been an emerging concern due to the increasing prevalence of transcatheter placement of pulmonary valve in the treatment of residual right ventricular outflow tract stenosis or regurgitation. Pulmonary valve endocarditis is a dreadful complication of transcatheter pulmonary valve implantation that have been reported with Melody valve (Medtronic, Inc., Minneapolis, MN) and Edward Sapien valve (Edwards Life Sciences, Irvine, CA) till date. There are scanty available literatures for pulmonary valve endocarditis with Venus P valve (Venus Medtech, Hangzhou, China) implantation. Furthermore, cardiovascular comorbidity is common in COVID-19 infection with limited evidence of COVID-19 infection concomitant with infective endocarditis. This case happens to be the first reported case of infective endocarditis of pulmonary valve with concomitant COVID-19 infection and also delayed presentation of pulmonary valve endocarditis with Venus P valve implantation.

Case report: Transcatheter pulmonary valve-in-valve implantation in a deteriorated self-expandable valve caused by infective endocarditis

“…IE of TPVI is a dreadful complication and associated with a relevant need of re-intervention ( 11 ). IE of Venus P valve with concomitant COVID-19 infection was also reported ( 12 ). In our case, the mechanism resulting in recurrence of pulmonary regurgitation after TPVI was IE, eventually leading to recurrence of pulmonary regurgitation and right heart failure.…”